MediFind
Condition

Common Variable Immune Deficiency

Latest Research

Latest Advance
Study
  • Condition: Common Variable Immune Deficiency-Associated Enteropathy (CVID)
  • Journal: Clinical immunology (Orlando, Fla.)
  • Treatment Used: Vedolizumab Therapy
  • Number of Patients: 7
  • Published —
This study tested the safety and efficacy of using a vedolizumab therapy to treat patients with CVID.
Latest Advance
Study
  • Condition: Chronic Spontaneous Urticaria (CSU) and Common Variable Immunodeficiency (CVID)
  • Journal: Frontiers in immunology
  • Treatment Used: Omalizumab
  • Number of Patients: 1
  • Published —
This case described a young adult female with chronic spontaneous urticaria (CSU) and common variable immunodeficiency (DVID) successfully treated with omalizumab.
Latest Advance
Study
  • Condition: Auto-Immune Hemolytic Anemia (AIHA) and Thrombocytopenia (ITP)
  • Journal: La Revue de medecine interne
  • Treatment Used: First-Line Corticosteroids, Second-Line Rituximab, and Third-Line Splenectomy
  • Number of Patients: 0
  • Published —
This study investigated the best treatment strategy for patients with common variable immunodeficiencies that develop AIHA and ITP.
Latest Advance
Study
  • Condition: Children with Primary Immunodeficiency Diseases
  • Journal: Immunotherapy
  • Treatment Used: Intravenous immunoglobulin (IVIG) 10%
  • Number of Patients: 25
  • Published —
This study assessed the safety and efficacy of an intravenous immunoglobulin (IVIG) 10% preparation (Panzyga®; Octapharma AG, Lachen, Switzerland) in predominantly antibody-deficient children with primary immunodeficiency disease.